The Wrong Question: We're Asking Whether SAAT Works Instead of Why It Stops Working

If you've spent any time in the Alpha-gal Syndrome community, you've almost certainly heard the debate surrounding Soliman Auricular Allergy Treatment (SAAT).

For some patients, it's described as life-changing. Others report little or no improvement, while many describe experiences somewhere in between. The conversation often becomes polarized, with patients trying to determine whether the treatment "works" or "doesn't work."

But after reviewing treatment surveys alongside patient narratives submitted to Tick Bite Data, we believe the conversation may be focused on the wrong question.

Perhaps the real question isn't whether SAAT works.

Perhaps it's: Who appears to benefit, how long do those benefits last, and what happens before symptoms return?

That subtle shift changes the entire direction of future research.

Instead of viewing treatment success as a simple yes-or-no outcome, it encourages us to understand Alpha-gal Syndrome as a condition that may evolve over time. It also recognizes that different patients may have very different experiences, even when receiving the same treatment.

Patient experiences are remarkably diverse

Our patient registry continues to reinforce something we've observed throughout our research: Alpha-gal Syndrome rarely follows the same path for every individual.

Some respondents describe dramatic improvements following SAAT. Others report being able to reintroduce foods they had avoided for years or experiencing meaningful improvements in quality of life. Still others report only partial improvement—or no improvement at all.

One respondent shared:

"SAAT gave me my life back. I was able to eat foods I never thought I'd eat again."

Another described a very different experience:

"I had improvement for a while, but after another tick bite everything came back."

Neither story defines the treatment.

Together, they illustrate why a simple success-or-failure label may not adequately capture the patient experience.

Looking beyond the initial treatment

As we reviewed narrative responses, another pattern began to emerge. Several respondents who initially described improvement also volunteered details about events that occurred before their symptoms returned. Although these experiences cannot establish cause and effect, similar themes appeared repeatedly across independent patient accounts.

Among the most commonly reported were:

• Additional tick bites

• Surgery

• COVID-19 or another significant illness

• Vaccination

• Major physiological or emotional stress

These recurring observations immediately raised a new question: Could the more important outcome be how long improvement lasts—and what might influence that durability?

At present, we simply don't know.

Why this deserves scientific attention

Alpha-gal Syndrome is an immune-mediated condition. Tick bites, viral infections, surgery, and other significant physiological events all involve activation of the immune system.

Could these events influence symptom recurrence after treatment? We don't know.

At this point, no conclusions can be drawn from patient-reported observations alone.

However, when independent patients repeatedly describe similar experiences without being prompted, those observations become valuable hypotheses worthy of scientific investigation.

That is how many important research questions begin.

This is where longitudinal research becomes essential

Most treatment studies answer a single question: Did the patient improve?

But what happens after that?

Six months later...

One year later...

Three years later...

Has the patient experienced another tick bite?

Did they undergo surgery?

Did they develop COVID-19 or another significant infection?

Have they experienced major physiological stress?

Has their Alpha-gal-specific IgE changed?

Traditional research often captures a snapshot in time.

Patients, however, continue living with their disease long after a study ends.

Understanding what happens after treatment may ultimately prove just as important as understanding the treatment itself.

The Financial Question Patients Are Also Asking

For many individuals living with Alpha-gal Syndrome, deciding whether to pursue SAAT isn't simply a medical decision—it's a financial one.

Unlike many conventional medical treatments, SAAT is often paid for out of pocket. Depending on the provider and treatment plan, patients may spend hundreds to well over a thousand dollars, with additional costs for travel, lodging, time away from work, and follow-up visits. Insurance coverage varies and, in many cases, patients report paying the full cost themselves.

For someone whose daily life has been profoundly affected by Alpha-gal Syndrome, that expense may feel like a worthwhile investment if it offers the possibility of returning to activities they once enjoyed.

But without long-term data, patients are often forced to make that decision with limited information.

The question isn't simply: "Does it work?"

Patients also want to know:

• If it helps, how long might the benefit last?

• Will additional treatment be needed?

• Could another tick bite change the outcome?

• Would I make the same decision again knowing what I know now?

• Was the improvement meaningful enough to justify the financial investment?

These are deeply personal decisions, and they're questions that patients deserve evidence to help answer.

A different way of measuring success

Rather than asking whether SAAT works, future research may be better served by asking more detailed questions.

Which patients report the greatest benefit?

How long do reported improvements last?

Do certain symptoms improve more than others?

Are there common events preceding symptom recurrence?

Do additional tick bites influence long-term outcomes?

Can laboratory markers such as Alpha-gal-specific IgE—or other emerging biomarkers—help explain why some patients maintain improvement while others do not?

These are questions that require patients to be followed over time—not simply evaluated once after treatment.

Why patient registries matter

One of the greatest strengths of patient registries is their ability to capture the lived experience of disease over months and years.

At Tick Bite Data, 75% of respondents have voluntarily sign up for future research, creating one of the largest patient follow-up cohorts in Alpha-gal Syndrome.

That allows us to ask questions traditional studies often cannot:

Did symptoms remain improved?

Did they change?

What happened in between?

Did another tick bite occur?

Was surgery performed?

Did another illness develop?

How did those events affect quality of life?

Longitudinal patient-reported registries help move the conversation beyond a single treatment outcome toward understanding the entire course of disease.

Looking forward

Our goal is not to determine whether any specific treatment should or should not be recommended. Rather, our mission is to identify meaningful patient-reported patterns that deserve further scientific investigation.

The stories shared through our registry suggest that future research should move beyond asking whether patients improved immediately after treatment. Instead, we should also be asking whether improvement persists, what factors may influence long-term outcomes, and why two patients receiving the same therapy may have very different experiences.

As our treatment registry continues to grow, we also hope to better understand:

• The typical out-of-pocket cost patients incur for SAAT.

• Whether insurance covers any portion of treatment.

• How long reported improvements last.

• Whether repeat treatments are common.

• What events patients report before symptoms recur.

• Whether patients felt the treatment was worth the financial investment.

These are practical questions that patients ask every day, yet they remain largely unanswered in the scientific literature.

The Bottom Line

The question may not simply be whether SAAT works. Instead it may be:

Who benefits?

How long do reported improvements last?

What events occur before symptoms return?

And for patients investing significant time, money, and hope into treatment—is the benefit meaningful enough to justify the cost?

These are questions that cannot be answered by a single office visit or a single survey.

They require listening to patients over time.

That is exactly what longitudinal patient registries are designed to do.

At Tick Bite Data, our goal is not to advocate for or against any particular treatment. Our goal is to ask better questions—questions that reflect the realities patients face every day and that can help guide future scientific research.

Because sometimes the most important discovery isn't finding the answer.

It's asking the right question first.

Help Advance Alpha-gal Syndrome Research

Every survey completed helps us better understand the patient experience and identify meaningful trends that may guide future research, improve awareness, and support better patient care.

New to Tick Bite Data?

If you have Alpha-gal Syndrome and haven't yet participated in our registry, we invite you to complete our comprehensive patient survey.

📝 Alpha-gal Survey

Already completed our Alpha-gal survey?

Thank you! Your participation is making a difference.

We also have two additional surveys designed to better understand the long-term patient experience.

🔗 Treatment Experience Survey Help us better understand treatments patients have tried—including SAAT, acupuncture, medications, supplements, and other approaches—and how those experiences have changed over time.

🔗 Ongoing Symptoms Survey Many patients continue to experience symptoms even after diagnosis or dietary changes. This survey focuses on persistent neurological, gastrointestinal, cardiovascular, musculoskeletal, and other ongoing symptoms to better understand the long-term burden of Alpha-gal Syndrome.

Every response matters. By sharing your experience, you're helping build one of the world's largest patient-reported Alpha-gal Syndrome registries and contributing to research that may improve understanding and care for patients today and in the future.

Tick Bite Data, Inc.A 501(c)(3) nonprofit organization dedicated to advancing the understanding of Alpha-gal Syndrome through patient-reported research.🌐 https://TickBiteData.com

References

• Tick Bite Data, Inc. Global Alpha-gal Syndrome Patient Registry (Treatment Experience Survey and Narrative Responses, accessed June 2026).

• Commins SP. Diagnosis and Management of Alpha-gal Syndrome.

• Wilson JM, Platts-Mills TAE, et al. Published literature on Alpha-gal Syndrome.

• American Academy of Allergy, Asthma & Immunology (AAAAI). Alpha-gal Syndrome resources.